<DOC>
	<DOCNO>NCT02320721</DOCNO>
	<brief_summary>Primary Objective : To demonstrate non-inferiority H0E901-U300 Lantus , change glycated hemoglobin A1c ( HbA1c ) Secondary Objectives : To demonstrate superiority H0E901-U300 comparison Lantus : - Percentage patient least one severe and/or confirm ( plasma glucose ≤70mg/dL [ 3.9mmol/L ] ) hypoglycemia event 22:00 08:59 next morning - Percentage patient least one nocturnal ( 00:00-05:59 ) severe and/or confirm ( ≤70mg/dL [ 3.9mmol/L ] ) hypoglycemia event - Percentage patient least one severe and/or confirm ( plasma glucose ≤70mg/dL [ 3.9mmol/L ] ) hypoglycemia event occur time day - HbA1c change</brief_summary>
	<brief_title>Comparison Safety Efficacy HOE901-U300 With Lantus Older Patients With Type2 Diabetes Insufficiently Controlled Their Current Antidiabetic Medications</brief_title>
	<detailed_description>The study consist 4-week screening period , 26-week treatment period compare HOE901-U300 Lantus , 2-day safety follow-up period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Inclusion criterion : Patients ≥65 year old type 2 diabetes mellitus , inadequately control antidiabetic regimen either include insulin , basal insulin insulin . Signed informed consent . Exclusion criterion : HbA1c screen visit : &lt; 7.0 % &gt; 10.0 % patient take basal insulin . &lt; 7.5 % &gt; 11.0 % insulinnaïve patient . History type 2 diabetes mellitus less 1 year screening . Patients stable basal insulin dose ( ±10 % last 8 week prior screen visit ) . Change dose antidiabetic treatment initiation new glucoselowering medication last 8 week prior screen . Chronic ( &gt; 10 day continuous use previous 6 month ) use bolus insulin injection , whether give separately part combination basal insulin , eg , premix insulin ; For insulinnaïve individual : current previous insulin use except maximum 10 consecutive day ( e.g . acute illness , surgery ) last year prior screen . Cognitive disorder dementia assess clinically MiniMental State Examination ( MMSE ) score &lt; 24 , neurologic disorder likely affect patient 's ability follow study procedure . The patient eligible despite MMSE score &lt; 24 investigator determines low score reflect educational cultural background dementia long patient otherwise able meet study requirement . Patients endstage renal disease ( &lt; 15 mL/min/1.73m^2 , per estimate Glomerular filtration rate [ eGFR ] measurement Modification Diet Renal Disease [ MDRD ] ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>